Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Asset Writedowns and Impairment (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Asset Writedowns and Impairment for 16 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 93.72% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $46.5 million, a 17.84% decrease, with the full-year FY2025 number at $319.4 million, up 464.31% from a year prior.
  • Asset Writedowns and Impairment was $2.7 million for Q4 2025 at Myriad Genetics, down from $43.0 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $43.0 million in Q4 2024 to a low of $800000.0 in Q3 2024.
  • A 4-year average of $9.2 million and a median of $4.7 million in 2021 define the central range for Asset Writedowns and Impairment.
  • Biggest YoY gain for Asset Writedowns and Impairment was 93.72% in 2025; the steepest drop was 93.72% in 2025.
  • Myriad Genetics' Asset Writedowns and Impairment stood at $4.7 million in 2021, then soared by 31.91% to $6.2 million in 2022, then surged by 593.55% to $43.0 million in 2024, then plummeted by 93.72% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Asset Writedowns and Impairment are $2.7 million (Q4 2025), $43.0 million (Q4 2024), and $800000.0 (Q3 2024).